Vincristine: clinical trials recruiting now
4
Recruiting trials
15
Conditions studied
9
US states with sites
2
Countries
FDA drug label
- FDA-approved
- Yes. Vincristine appears in the FDA drug-label database. Marketed as VinCRIStine Sulfate.
- Boxed warning
- The FDA label for Vincristine carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.
Phase breakdown
Early Phase 1 1
Phase 1 1
Phase 2 1
Phase 3 1
Conditions being studied
Recruiting trials involving Vincristine
- A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- The CARDIOPROTECT Trial
Common questions
Is Vincristine FDA-approved?
Yes, marketed as VinCRIStine Sulfate. Its FDA label carries a boxed warning.
How many recruiting trials involve Vincristine?
4 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.